Teva considering potential sale of inflammatory bowel disease asset - Bloomberg

• Teva Pharmaceutical Industries (NYSE:TEVA) is considering options for its inflammatory bowel disease candidate TEV 48574, including a potential sale.
• The anti-TL1A is in phase 2 for ulcerative colitis and Crohn's disease.
• Bloomberg reported the Israeli pharma has been having discussions with advisors on a partnership or sale of the candidate.
• Other companies with candidates targeting TL1A for inflammatory bowel diseases include Prometheus Biosciences (RXDX) PRA023 and Roivant Sciences' (ROIV) RVT-3101.

More on anti-TL1A therapies

• Pfizer, Roivant launch subsidiary focused on ulcerative colitis

• Prometheus Biosciences A Buy On Positive Phase 2 Data

• Teva gains after announcing new growth strategy; Evercore upgrades